Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BeiGene Bags $750m, Sees China Reforms Creating New Opportunities

Executive Summary

A spectacular secondary offering will enable Beijing-based BeiGene to expand in both novel R&D and manufacturing in 2018, driven largely by an integrated China-global approach, its CFO says.

Advertisement

Related Content

Keeping Track: FDA's Review Actions Carry On During Shutdown
A Safe Harbor For Biotechs? Ascletis, BeiGene Mark Early Wins For HK Exchange
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Mehta Analysis: China, A Populist Pharma Power
2017 A Takeoff Year For China Drug Approvals?
Go Local And Stay Flexible: Unlocking Market Access For Novel Drugs In China

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel